Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "9333-1"

Looking for quality documents?
store icon
Tube-A-Lyzer Dialysis Device – Repligen
Tube-A-Lyzer is a ready-to-use, gentle separation device that combines convenience and disposability with the efficiency of dynamic dialysis to significantly increase the mass transfer rate and reduce the overall dialysis from 1-2 days to 12 hours. This self-contained, disposable device incorporates a semi-permeable membrane tubing that separates the sample chamber from the surrounding flow-through buffer chamber. The dry Biotech Grade Cellulose Ester (CE) membrane tubing is available in 6 MWCOs and the membrane-defined sample chamber is available in 2 volume sizes. The sample port provides easy access for loading, recovering and in-process testing. The housing is designed to be a flow-through dialysate chamber that can be connected to a buffer source and a waste collection vessel, or for discharging directly to drain. Tube-A-Lyzer is non-pyrogenic and can be sterilized (25 kGy gamma irradiation).
external link icon
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences. William Blair 41 st Annual Growth Stock conference being held June 1 - 3.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, June 1, at 1:40 p.m. EST.   Jefferies Virtual Healthcare Conference being held June 1 - 3.   Tony J. Hunt, President and Chief Executive Officer and Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Thursday, June 3, at 2:30 p.m. EST. A live webcast of the discussions will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences
external link icon
Repligen Announces CEO Transition Plan
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors (“Board”) has approved the planned transition of Tony J. Hunt from Chief Executive Officer (“CEO”) to Executive Chair, effective September 1, 2024. The Company’s Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of Lead Independent Director.
Mr. Hunt has served as Chief Executive Officer and a member of the Company’s Board of
external link icon
Repligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021
WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) today announced the pricing of an underwritten public offering of $100 million aggregate principal amount of 2.125% Convertible Senior Notes due 2021 (the “Notes”). The Company has granted the underwriters a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes. The offering is expected to close on or about May 24, 2016, subject to customary closing conditions. Jefferies is acting as the sole book-running manager, and Janney Montgomery Scott and Craig-Hallum Capital Group are acting as co-managers in the offering.  Perella Weinberg Partners LP and J. Wood Capital Advisors LLC are serving as financial advisors to the Company in connection with the offering.
Interest on the Notes will be paid semiannually in arrears on June 1 and December 1 of each year at the rate of 2.125% per year, beginning on December 1, 2016. The Notes will
external link icon
Repligen Acquires Atoll GmbH
WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired Atoll GmBH (“Atoll”) of Weingarten, Germany, an innovator and manufacturer of MediaScout® pre-packed chromatography columns used in process development and clinical manufacturing of biologic drugs. The acquisition of Atoll expands Repligen’s pre-packed column chromatography portfolio into high throughput process development screening, complementing the Company’s existing strength in clinical production-scale columns. The combined offering will provide bioprocessing customers with breadth and flexibility in choosing column size, chromatography media and packed bed formats.   Repligen purchased Atoll from UV-Cap GmbH & Co. KG on April 1, 2016 for a combination of $9.1 million in cash and 538,700 shares 1  of Repligen common stock, for total upfront consideration of approximately
external link icon
Repligen to Report Third Quarter 2018 Financial Results
- Webcast and Conference Call to Be Held Thursday, November 1, 2018 at 8:30 a.m. EDT - WALTHAM, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter of 2018 financial results on Thursday, November 1, 2018. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine-month reporting periods ended September 30, 2018. 

The conference call will be accessible by dialing toll-free (866) 777-2509 for domestic callers and (412) 317-5413 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the
external link icon
Repligen to Report First Quarter 2024 Financial Results
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2024.
The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in
external link icon
Repligen to Report Third Quarter 2022 Financial Results
Webcast and Conference Call to Be Held Tuesday, November 1, 2022 at 8:30 a.m. EDT WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2022 financial results on Tuesday, November 1, 2022. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2022. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for
publications icon
Continuous Bioprocessing: Current Practice And Future Potential Publication
E-book Volume 1 2014 Compiled by John Bonham-Carter, Repligen Chapters Introduction to Continuous Manufacturing:Technology Landscape and Trends Eric S. Langer and Ronald A. Rader, BioPlan Associates A Brief History of Perfusion Biomanufacturing Jerry Shevitz and John Bonham-Carter, Refine Technology Bioreactor Configuration and Operation Christel Fenge, Jörg Weyand, Gerhard Greller, Thorsten Adams, Sartorius Stedim Biotech How to Develop a Perfusion Process Véronique Chotteau, Royal Technical University, KTH Case Study: Optimized Perfusion Shaun Eckerle, Gallus BioPharmaceuticals Process Intensification Approaches for Cost Sensitive Protein Applications Willem Adriaan de Jongh, Expres2ion Biotechnologies Impact of Single-use Technology on Continuous Biorocessing William G. Whitford, Thermo Fisher Scientific Continuous Multicolumn Chromatography Processes Marc Bisschops, Tarpon Biosystems Continuous Processes: Economic Evaluation Andrew Sinclair and Andrew Brown, BioPharm Services Vision: Integrating Upstream and Downstream in a Fully Continuous Facility Tim Johnson, Genzyme